GlassScriptPhysician profile
Anish Vani
NPI 1003227000
$8,570.89
in general payments reported to CMS, 2019-2025
27 companies · $1,682 in 2025
The $1,682 reported for 2025 was more than what 81% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $319 · 2022: $1,803 · 2023: $1,765 · 2024: $3,002 · 2025: $1,682.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,330 · Consulting Fee: $119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,330.07 |
| Consulting Fee | $118.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,136.40 | 2022-2025 | Repatha, Repatha |
| Heartflow, INC. | $1,551.63 | 2022-2025 | Ffrct |
| Novartis Pharmaceuticals Corporation | $1,053.68 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $683.84 | 2022-2024 | Xarelto |
| Boston Scientific Corporation | $616.93 | 2021-2025 | Watchman Flx, Watchman Access System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $337.70 | 2022-2024 | Jardiance |
| Esperion Therapeutics, INC. | $290.54 | 2022-2025 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $255.42 | 2022-2025 | Farxiga, Wainua |
| Novo Nordisk INC | $238.47 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Abbott Laboratories | $213.38 | 2021 | |
| Amarin Pharma, INC. | $207.57 | 2022-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $117.65 | 2021-2025 | Lifevest |
| Scpharmaceuticals INC. | $108.25 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $95.42 | 2024-2025 | Evkeeza, Praluent |
| Kowa Pharmaceuticals America, INC. | $74.98 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $73.41 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $70.63 | 2023-2024 | Verquvo |
| Kiniksa Pharmaceuticals International, Plc | $65.79 | 2024 | Arcalyst |
| Kestra Medical Technology Services, INC. | $63.68 | 2023 | Assure Wcd |
| Bridgebio Pharma, INC. | $62.60 | 2025 | Attruby |
| E.R. Squibb & Sons, L.L.C. | $59.17 | 2024 | Eliquis, Camzyos |
| Chiesi USA, INC. | $52.40 | 2024-2025 | Juxtapid |
| Abiomed | $45.19 | 2021 | |
| Mannkind Corporation | $33.81 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $25.16 | 2024 | Inpefa |
| Ionis Pharmaceuticals, INC. | $19.89 | 2025 | Tryngolza |
| Xeris Pharmaceuticals, INC. | $17.30 | 2023 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anish Vani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.